Download Read More… - Envisia Therapeutics

ENVISIA THERAPEUTICS TO PRESENT NEW GLAUCOMA AND AMD DATA AT ARVO 2014
Company to Make Eight Presentations at World’s Largest International Ophthalmology Conference
RESEARCH TRIANGLE PARK, NC – May 1, 2014 – Envisia Therapeutics today announced that it will
present data for its next generation product candidates, ENV515 for glaucoma and ENV705 for agerelated macular degeneration (AMD), as well as new data for the company’s novel drug delivery systems
designed for the posterior and anterior segments of the eye, at the Association for Research in Vision
and Ophthalmology (ARVO) 2014 Annual Meeting. ARVO is globally recognized and respected as a
leading provider of quality content and research, and the annual meeting is the industry’s premier
gathering place for information exchange and networking. ARVO 2014 is being held May 4-8, 2014 in
Orlando, FL.
“Envisia is extremely proud to have such a great showing of data at the ARVO 2014 Annual Meeting,
which is revered by both scientists and practitioners internationally,” said Ben Yerxa, PhD, Chief
Scientific Officer of Envisia. “We believe our technology provides a white space of opportunity that will
pave the way for the next generation of ophthalmology products that have the potential to improve
patient safety and outcomes.”
Tomas Navratil, Ph.D., Envisia’s Vice President of Development, will give an oral presentation titled
Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment
of Glaucoma Targeting Six-Month Duration of Action on Tuesday May 6th at 4:15PM in Room S310A-D.
In addition, the company will present data supporting the following abstracts titled:
Glaucoma:
- Precisely Engineered Biodegradable Drug Delivery Systems for the Extended Release of
Prostaglandin Analogues in the Anterior Chamber
- Intracameral Conversion of Travoprost to Travoprost Acid in the Normotensive Beagle Dog
Model
AMD:
- Extended Release of Microfabricated Protein Particles from Biodegradable Hydrogel Implants
for the Treatment of Age-Related Macular Degeneration
- Biodegradable Hydrophobic Intravitreal Implants for the Extended Release of Bevacizumab for
Age-Related Macular Degeneration
-
Development of Precisely-Engineered Biodegradable Drug Delivery Systems for Posterior
Ocular Drug Delivery: PRINT® PLGA Extended Release Implants for anti-VEGF Biologics
Photocurable Hydrogel Implants for the Extended Release of Bevacizumab for the Treatment
of Age-Related Macular Degeneration
Post-operative Inflammation and Pain:
- Controlled and Extended Release of Difluprednate from Biodegradable Intraocular Implants
Engineered using PRINT® Technology
Envisia uses the power of the proprietary PRINT® (Particle Replication In Non-Wetting Templates)
technology to create particle-based ocular therapeutics that can deliver both small and large molecules
in multiple formats.
Envisia’s lead product, ENV515, is a marketed prostaglandin analogue that uses a proprietary, fully
biodegradable PRINT particle formulation to provide sustained intraocular pressure (IOP) reduction over
many months, offering the potential to address the poor compliance that exists today and to limit
glaucoma progression and vision loss. Envisia is also exploring how the company’s unique technology
can address other important ocular diseases, such as AMD and ocular inflammation.
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology
company focused on the development of novel ocular therapies. Envisia is leveraging the unique and
powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions,
beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of a
marketed prostaglandin analogue with the potential to significantly limit disease progression and vision
loss through improved product performance and patient compliance. Envisia is located in Research
Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
Envisia Therapeutics Media Contact:
Michael Parks
484.356.7105
[email protected]